Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced computational platform for drug discovery.
Versant Ventures, through a $20m Series A financing, has launched Black Diamond Therapeutics, a biotechnology company focused on developing a new type of precision medicine for cancer.
e-therapeutics has entered into a research collaboration with Danish drug manufacturer Novo Nordisk to discover biological mechanisms and therapies to treat type-2 diabetes.
UK-based clinical-stage biopharmaceutical firm Mereo BioPharma Group and oncology-focused clinical stage biopharmaceutical business OncoMed Pharmaceuticals have agreed to merge.
Global biopharmaceutical company UCB is investing around £1bn in the UK for research and development, supporting the country’s life sciences sector.
Alphabet-owned DeepMind has claimed that research powered by artificial intelligence (AI) can help to predict the 3D structure of a protein on just its genetic sequence.
TRIGR Therapeutics has expanded bispecific immuno-oncology pipeline with exclusive global license of clinical stage, dual angiogenesis inhibitor from ABL Bio.
British drugmaker GlaxoSmithKline (GSK) has agreed to acquire US-based oncology-focused biopharmaceutical firm, Tesaro, for around £4bn ($5.1bn).
Aprea Therapeutics, a biopharmaceutical company engaged in the discovery and development of anticancer compounds that reactivate the tumor suppressor protein, p53, has closed a €50m Series C financing round.
WuXi Biologics and ABL Bio have entered into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.